Related Experiment Video
Updated: Jul 31, 2025
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
Acceptance, commissioning and quality assurance of the MRIdian®: Site experience and three years follow-up
S Valdenaire1, O Riou1, N Aillères1
1Institut du Cancer de Montpellier (ICM), Montpellier, France.
Purpose:
This study presents the methodology and results of the acceptance and periodical quality controls on the MRIdian®.
Materials And Methods:
The impact of the magnetic field on other machines was investigated by controlling nearby linacs dose profiles. The image quality of the 0.345T MR scanner was evaluated, also assessing the integrated linear accelerator influence. The photon beams lateral and depth dose profiles were measured in motorized water tanks, along dose rate and output factors, and compared to Monte Carlo (MC) calculations. The isocenter position, gantry angles and multi-leaf collimator (MLC) position were controlled using film dosimetry. Gating latency and dosimetric accuracy were controlled with a dynamic phantom.
Results:
The magnetic field had no significant impact on other nearby linacs. Image quality was within tolerances and did not vary over time. Dose profiles measured showed good agreement with MC data, with maximum differences of 1.3% in-field. Output factors were within 0.8% of calculated values. Imaging and radiative isocenter matched within 0.9±0.4mm over all monthly controls. Gantry rotation was precise within -0.1±0.2°, with an isocenter variation of 1.4±0.3mm diameter. The average MLC position was within 0.4±0.1mm of theoretical value. Finally, the gating latency was 0.14±0.07sec and the gated dose within 0.3% of base value.
Conclusion:
All results are within the tolerances fixed by ViewRay® and show low variations over 2 years, comforting the use of small margins and gating for high-dose adaptive treatments.
